Literature DB >> 22869581

Pharmacokinetics and pharmacodynamics of oral artesunate monotherapy in patients with uncomplicated Plasmodium falciparum malaria in western Cambodia.

David Saunders1, Phisit Khemawoot, Pattaraporn Vanachayangkul, Raveewan Siripokasupkul, Delia Bethell, Stuart Tyner, Youry Se, Wiriya Rutvisuttinunt, Sabaithip Sriwichai, Lon Chanthap, Jessica Lin, Ans Timmermans, Doung Socheat, Pascal Ringwald, Harald Noedl, Bryan Smith, Mark Fukuda, Paktiya Teja-Isavadharm.   

Abstract

Artemisinin-resistant malaria along the Thailand-Cambodian border is an important public health concern, yet mechanisms of drug action and their contributions to the development of resistance are poorly understood. The pharmacokinetics and pharmacodynamics of oral artesunate monotherapy were explored in a dose-ranging trial in an area of emerging artesunate resistance in western Cambodia. We enrolled 143 evaluable subjects with uncomplicated Plasmodium falciparum malaria in an open label study of directly observed artesunate monotherapy at 3 dose levels (2, 4, and 6 mg/kg of body weight/day) for 7 days at Tasanh Health Center, Tasanh, Cambodia. Clinical outcomes were similar among the 3 groups. Wide variability in artesunate and dihydroartemisinin concentrations in plasma was observed. No significant dose-effect or concentration-effect relationships between pharmacokinetic (PK) and parasite clearance parameters were observed, though baseline parasitemia was modestly correlated with increased parasite clearance times. The overall parasite clearance times were prolonged compared with the clearance times in a previous study at this site in 2006 to 2007, but this did not persist when the evaluation was limited to subjects with a comparable artesunate dose (4 mg/kg/day) and baseline parasitemia from the two studies. Reduced plasma drug levels with higher presentation parasitemias, previously hypothesized to result from partitioning into infected red blood cells, was not observed in this population with uncomplicated malaria. Neither in vitro parasite susceptibility nor plasma drug concentrations appeared to have a direct relationship with the pharmacodynamic (PD) effects of oral artesunate on malaria parasites. While direct concentration-effect relationships were not found, it remains possible that a population PK modeling approach that allows modeling of greater dose separation might discern more-subtle relationships.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22869581      PMCID: PMC3486599          DOI: 10.1128/AAC.00044-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  A histidine-rich protein 2-based malaria drug sensitivity assay for field use.

Authors:  Harald Noedl; Bernhard Attlmayr; Walther H Wernsdorfer; Herwig Kollaritsch; Robert S Miller
Journal:  Am J Trop Med Hyg       Date:  2004-12       Impact factor: 2.345

2.  Evidence of artemisinin-resistant malaria in western Cambodia.

Authors:  Harald Noedl; Youry Se; Kurt Schaecher; Bryan L Smith; Duong Socheat; Mark M Fukuda
Journal:  N Engl J Med       Date:  2008-12-08       Impact factor: 91.245

3.  A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction.

Authors:  Toufigh Gordi; Rujia Xie; Nguyen V Huong; Dinh X Huong; Mats O Karlsson; Michael Ashton
Journal:  Br J Clin Pharmacol       Date:  2005-02       Impact factor: 4.335

4.  Population pharmacokinetics and pharmacodynamics of artemether and lumefantrine during combination treatment in children with uncomplicated falciparum malaria in Tanzania.

Authors:  Sofia Friberg Hietala; Andreas Mårtensson; Billy Ngasala; Sabina Dahlström; Niklas Lindegårdh; Anna Annerberg; Zul Premji; Anna Färnert; Pedro Gil; Anders Björkman; Michael Ashton
Journal:  Antimicrob Agents Chemother       Date:  2010-08-16       Impact factor: 5.191

5.  Population pharmacokinetics of artesunate and dihydroartemisinin following single- and multiple-dosing of oral artesunate in healthy subjects.

Authors:  Beesan Tan; Himanshu Naik; In-Jin Jang; Kyung-Sang Yu; Lee E Kirsch; Chang-Sik Shin; J Carl Craft; Lawrence Fleckenstein
Journal:  Malar J       Date:  2009-12-18       Impact factor: 2.979

6.  Artemisinin resistance in Plasmodium falciparum malaria.

Authors:  Arjen M Dondorp; François Nosten; Poravuth Yi; Debashish Das; Aung Phae Phyo; Joel Tarning; Khin Maung Lwin; Frederic Ariey; Warunee Hanpithakpong; Sue J Lee; Pascal Ringwald; Kamolrat Silamut; Mallika Imwong; Kesinee Chotivanich; Pharath Lim; Trent Herdman; Sen Sam An; Shunmay Yeung; Pratap Singhasivanon; Nicholas P J Day; Niklas Lindegardh; Duong Socheat; Nicholas J White
Journal:  N Engl J Med       Date:  2009-07-30       Impact factor: 91.245

7.  Pharmacokinetic profiles of artesunate after single intravenous doses at 0.5, 1, 2, 4, and 8 mg/kg in healthy volunteers: a phase I study.

Authors:  Qigui Li; Louis R Cantilena; Kevin J Leary; George A Saviolakis; R Scott Miller; Victor Melendez; Peter J Weina
Journal:  Am J Trop Med Hyg       Date:  2009-10       Impact factor: 2.345

8.  Absence of time-dependent artesunate pharmacokinetics in healthy subjects during 5-day oral administration.

Authors:  L T Diem Thuy; L Ngoc Hung; P T Danh; K Na-Bangchang
Journal:  Eur J Clin Pharmacol       Date:  2008-07-04       Impact factor: 2.953

Review 9.  What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs.

Authors:  Sarah J Roffey; R Scott Obach; Jenny I Gedge; Dennis A Smith
Journal:  Drug Metab Rev       Date:  2007       Impact factor: 4.518

10.  Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers.

Authors:  Catherine Orrell; Francesca Little; Peter Smith; Peter Folb; Walter Taylor; Piero Olliaro; Karen I Barnes
Journal:  Eur J Clin Pharmacol       Date:  2008-04-16       Impact factor: 2.953

View more
  13 in total

1.  Effects of body size and gender on the population pharmacokinetics of artesunate and its active metabolite dihydroartemisinin in pediatric malaria patients.

Authors:  Carrie A Morris; Beesan Tan; Stephan Duparc; Isabelle Borghini-Fuhrer; Donald Jung; Chang-Sik Shin; Lawrence Fleckenstein
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

2.  Artemisinin resistance phenotypes and K13 inheritance in a Plasmodium falciparum cross and Aotus model.

Authors:  Juliana M Sá; Sarah R Kaslow; Michael A Krause; Viviana A Melendez-Muniz; Rebecca E Salzman; Whitney A Kite; Min Zhang; Roberto R Moraes Barros; Jianbing Mu; Paul K Han; J Patrick Mershon; Christine E Figan; Ramoncito L Caleon; Rifat S Rahman; Tyler J Gibson; Chanaki Amaratunga; Erika P Nishiguchi; Kimberly F Breglio; Theresa M Engels; Soundarapandian Velmurugan; Stacy Ricklefs; Judith Straimer; Nina F Gnädig; Bingbing Deng; Anna Liu; Ababacar Diouf; Kazutoyo Miura; Gregory S Tullo; Richard T Eastman; Sumana Chakravarty; Eric R James; Kenneth Udenze; Suzanne Li; Daniel E Sturdevant; Robert W Gwadz; Stephen F Porcella; Carole A Long; David A Fidock; Marvin L Thomas; Michael P Fay; B Kim Lee Sim; Stephen L Hoffman; John H Adams; Rick M Fairhurst; Xin-Zhuan Su; Thomas E Wellems
Journal:  Proc Natl Acad Sci U S A       Date:  2018-11-19       Impact factor: 11.205

3.  Evaluation of artemisinins for the treatment of acute myeloid leukemia.

Authors:  Christina D Drenberg; Jassada Buaboonnam; Shelley J Orwick; Shuiying Hu; Lie Li; Yiping Fan; Anang A Shelat; R Kiplin Guy; Jeffrey Rubnitz; Sharyn D Baker
Journal:  Cancer Chemother Pharmacol       Date:  2016-04-28       Impact factor: 3.333

4.  How Robust Are Malaria Parasite Clearance Rates as Indicators of Drug Effectiveness and Resistance?

Authors:  Ian M Hastings; Katherine Kay; Eva Maria Hodel
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

5.  Opposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation.

Authors:  Frank Kloprogge; Rose McGready; Aung Pyae Phyo; Marcus J Rijken; Warunee Hanpithakpon; Hla Hla Than; Nathar Hlaing; Naw Thida Zin; Nicholas P J Day; Nicholas J White; François Nosten; Joel Tarning
Journal:  Br J Clin Pharmacol       Date:  2015-07-22       Impact factor: 4.335

6.  Comparative pharmacokinetics and pharmacodynamics of intravenous artelinate versus artesunate in uncomplicated Plasmodium coatneyi-infected rhesus monkey model.

Authors:  Paktiya Teja-Isavadharm; Duangsuda Siriyanonda; Maneerat Rasameesoraj; Amporn Limsalakpeth; Nitima Chanarat; Natthasorn Komcharoen; Peter J Weina; David L Saunders; Montip Gettayacamin; R Scott Miller
Journal:  Malar J       Date:  2016-09-06       Impact factor: 2.979

7.  Prolonged parasite clearance in a Chinese splenectomized patient with falciparum malaria imported from Nigeria.

Authors:  Hong-Wei Zhang; San-Jin Li; Tao Hu; Yong-Min Yu; Cheng-Yun Yang; Rui-Min Zhou; Ying Liu; Jing Tang; Jing-Jing Wang; Xiu-Yun Wang; Yong-Xiang Sun; Zhan-Chun Feng; Bian-Li Xu
Journal:  Infect Dis Poverty       Date:  2017-04-04       Impact factor: 4.520

8.  School-aged children based seasonal malaria chemoprevention using artesunate-amodiaquine in Mali.

Authors:  Mahamadou A Thera; Abdoulaye K Kone; Bourama Tangara; Elizabeth Diarra; Sirama Niare; Abdramane Dembele; Mahamadou S Sissoko; Ogobara K Doumbo
Journal:  Parasite Epidemiol Control       Date:  2018-02-07

9.  Efficacy of two versus three-day regimens of dihydroartemisinin-piperaquine for uncomplicated malaria in military personnel in northern Cambodia: an open-label randomized trial.

Authors:  Chanthap Lon; Jessica E Manning; Pattaraporn Vanachayangkul; Mary So; Darapiseth Sea; Youry Se; Panita Gosi; Charlotte Lanteri; Suwanna Chaorattanakawee; Sabaithip Sriwichai; Soklyda Chann; Worachet Kuntawunginn; Nillawan Buathong; Samon Nou; Douglas S Walsh; Stuart D Tyner; Jonathan J Juliano; Jessica Lin; Michele Spring; Delia Bethell; Jaranit Kaewkungwal; Douglas Tang; Char Meng Chuor; Prom Satharath; David Saunders
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

10.  Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence.

Authors:  Nancy Berte; Stefanie Lokan; Marcus Eich; Ella Kim; Bernd Kaina
Journal:  Oncotarget       Date:  2016-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.